Ligand Announces Successful Phase II Results for Captisol[R]-Enabled Propylene Glycol-Free Melphalan.
Business Wire › November 02, 2011
Linked as:
Extract
Ligand Announces Successful Phase II Results for Captisol[R]-Enabled Propylene Glycol-Free Melphalan.
SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced data from the Phase II study with its Captisol-enabled([R]), propylene glycol-free (PG-free) melphalan.
This Phase II study compared the safety, tolerability and pharmacokinetic profiles of a new PG-free melphalan intravenous formulation and the current clinically used intravenous formulation of melphalan (sold as Alkeran[R]) for multip...See the full content of this document
Sponsored links
